ParasocialDownload on theApp Store

No Priors: Artificial Intelligence | Technology | Startups

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg

39 min

3 min preview

Listen to the full episode

Do not have it yet? Parasocial is a podcast player by Super Simple.

About this episode

Drug discovery and development has long relied on expensive, time-consuming empirical trial and error. By shifting the discovery process onto computers, Isomorphic Labs wants to fundamentally change medicine from a process of discovery to one of precision engineering. Elad Gil sits down with Isomorphic’s president Max Jaderberg to discuss his vision for using predictive AI models to achieve experimental accuracy. Max details how the success of AlphaFold provided the first proof of concept that a deep learning model could generalize in the field of biology, and how an AI model’s compounding of learnings allows it to achieve generalizability with scale, thus greatly increasing the probability of success as well as speed in real world clinical trials. He also talks about evolving past the need for animal testing through in-silico models, Isomorphic’s focus on developing drug design engines that are agnostic of disease area, target class, and modality, why accurate molecule engineering unlocks the potential for multidrug cocktails that span complex biological pathways, and how he believes AI molecule optimization will improve both human lifespan and healthspan. Sign up for new podcast

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg — No Priors: Artificial Intelligence | Technology | Startups